Curcumin acts synergistically with fluconazole to sensitize a clinical isolate of Candida albicans showing a MDR phenotype

Medical Mycology

Volumn 50, Issue 1, 2012, Pages 26-32

  Garcia Gomes, A S ^a   Curvelo, J A R ^b   Soares, R M A ^b   Ferreira Pereira, A ^a  

^a IMPPG   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

ATP binding cassette superfamily; Candida albicans; efflux pumps; major facilitator superfamily; resistance; synergism

Indexed keywords

CURCUMIN; FLUCONAZOLE; ITRACONAZOLE; RHODAMINE 6G;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG DETERMINATION; DRUG POTENTIATION; DRUG SENSITIZATION; FUNGUS ISOLATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; SACCHAROMYCES CEREVISIAE;

ANTIFUNGAL AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CANDIDA ALBICANS; CURCUMA; CURCUMIN; DRUG RESISTANCE, MULTIPLE, FUNGAL; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; PLANT EXTRACTS;

EID: 83755188657     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2011.578156     Document Type: Article

References (51)

1. Pfaller MA, Messer SA, Boyken L, e t al. Caspafungin activity against clinical isolates of fl uconazole-resistant Candida. J Clin Microbiol 2003; 41: 5729-5731. (Pubitemid 37543273)
2. Karkowska-Kuleta J, Rapala-Kozik M, Kozik A. Fungi pathogenic to humans: molecular bases of virulence of Candida albicans Cryptococcus neoformans and Aspergillus fumigatus. Acta Biochim Polon 2009; 55: 211-224.
3. Pfaller MA, Lockhart SR, Pujol C, et al. Hospital specifi city, region specifi city, and fl uconazole resistance of Candida albicans bloodstream isolates. J Clin Microb 1998; 36: 1518-1529. (Pubitemid 28226023)
4. Eggimann P, Garbino J, Pittet D. Management of C andida species infections in critically ill patients. Lancet Infect Dis 2003; 3: 772-785. (Pubitemid 37489961)
5. Olaechea PM, Palomar M, Leon-Gil C, et al. Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis 2004; 23: 323-330. (Pubitemid 38669943)
6. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med 2006; 34: 857-863.
7. Leroy O, Gangneux JP, Montravers P, e t al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005 - 2006). Crit Care Med 2009; 37: 1612-1618.
8. Perfect JR, Casadevall A. Fungal molecular pathogenesis: what can it do and why do we need it? In: Heitman J (ed.), Molecular Principles of Fungal Pathogenesis. Washington, DC: ASM Press, 2006; 3-11.
9. Mavor AL, Thewes S, Hube B. Systemic fungal infections caused by Candida species: Epidemiology, infection process and virulence attributes. Curr Drug Targets 2005; 6: 863-874. (Pubitemid 41672448)
10. Guo XL, Leng P, Yang Y, Lou HX. Plagiochin E, a botanic-derived phenolic compound, reverses fungal resistance to fl uconazole relating to the effl ux pump. J Appl Microbiol 2008; 104: 831-838. (Pubitemid 351257751)
11. Sanglard D, Odds FC. Resistance of C andida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002; 2: 73-85. (Pubitemid 36114141)
12. Richardson K. The discovery and profi le of fl uconazole. J Chemother 1990; 2: 51-54.
13. Charlier C, Hart E, Lefort A, e t al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006; 57: 384-410. (Pubitemid 43240191)
14. Perea S, Lopez-Ribot JL, Kirkpatrick WR, et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strain displaying high-level fl uconazole resistance isolated from human immunodefi ciency virus-infected patients. Antimicrob Agents Chemother 2001; 45: 2676-2684. (Pubitemid 32906656)
15. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. J Clin Microbiol 1998; 11: 382-402. (Pubitemid 28197359)
16. Prasad R, Dewergifosse P, Goffeau A, Balzi E. Molecular cloning and characterization of a novel gene of Candida albicans CDR1, conferring multiple resistance to drugs and antifungals. Curr Genet 1995; 27: 320-329.
17. Sanglard D, Kuchler K, Ischer, F et al. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specifi c multidrug transporters. Antimicrob Agents Chemother 1995; 39: 2378-2386.
18. Sanglard D, Ischer F, Monod M, Billie J. Cloning of C andida albicans genes conferring resistance to azole antifungal agents: Characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 1997; 143: 405-416. (Pubitemid 27092176)
19. Morschh ä user, J. The genetic basis of fl uconazole resistance development in Candida albicans. Biochim Biophys Acta 2002; 1587: 240-248. (Pubitemid 34655792)
20. Sharma M, Manoharlal R, Shukla S, et al. Curcumin modulates effl ux mediated by yeast ABC multidrug transporters and is synergistic with antifungals. Antimicrob Agen Chem 2009; 53: 3256-3265
21. Petrikkos G, Skiada A. Recent advances in antifungal chemotherapy. Int J Antimicrob Agen 2007; 30: 107-108.
22. Julie S, Jurenka MT. Anti-infl ammatory properties of curcumin, a major constituent of Curcuma longa: A review of preclinical and clinical research. Altern Med Rev 2009; 14: 141-153.
23. Rowe DL, Ozbay T, O Regan RM, Nahta R. Modulation of the BRCA1 protein and induction of apoptosis in triple negative breast cancer cell lines by the polyphenolic compound curcumin. Breast Cancer 2009; 2: 61-75.
24. Limtrakul P, Anuchapreeda S, Buddhasukh D. Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. BMC Cancer 2004; 4: 1-6.
25. Govindarajan VS. Turmeric: Chemistry, technology and quality. C rit Rev Food Sci Nutr 1990; 12: 199-301.
26. Ammon HPT, Wahl MA. Pharmacology of Curcuma longa. P lanta Med 1991; 57: 1-7.
27. Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 2008; 10: 511-545.
28. Qureshi S, Shah AH, Ageel AM. Toxicity studies on Alpinia galangal and Curcuma longa. Planta Med 1992; 58: 124-127.
29. Shankar TN, Shantha NV, Ramesh HP, Murthy IA, Murthy VS. Toxicity studies on turmeric: Acute toxicity studies in rats, guinea pigs and monkeys. Indian J Exp Biol 1980; 18: 73-75. (Pubitemid 10143537)
30. Braga-Silva LA, Santos ALS, Portela MB, Souto-Padron TCB, Araujo Soares RM. Effect of suramin on the human pathogen Candida albicans: implications on the fungal development and virulence. FEMS Immunol Med Microbiol 2007; 51: 399-406 (Pubitemid 47547518)
31. National Commitee for Clinical Laboratory Standards. R eference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts 2nd ed. Approved standard M27-A2. Wayne, PA: National Committee for Clinical Laboratory Standards 2002.
32. Yamamoto S, Hiraga K, Abiko A, Hamanaka M, Oda K. A new function of isonitrile as an inhibitor of the Pdr5p multidrug ABC transporter in Saccharomyces cerevisiae. Biochem Biophys Res 2005; 330: 622-628. (Pubitemid 40417691)
33. Orhan G, Bayram A, Zer Y. Synergy test by E test and checkerboard methods of antimicrobial combinations against Brucella melitensis. J Clin Microbiol 2005; 43: 140-143. (Pubitemid 40096291)
34. Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum Ml. Combination treatment of invasive fungal infections. Clin Microbiol Rev 2005; 18: 163-194. (Pubitemid 40170667)
35. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1. (Pubitemid 36850074)
36. Maesaki SP, Marichal H, Vanden Bossche D, Sanglard D, Kohno S. Rhodamine 6G effl ux for the detection of CDR1-overexpressing azole-resistant Candida albicans strains. J Antimicrob Chemother 1999; 44: 27-31. (Pubitemid 29353679)
37. Nakamura K, Niimi M, Niimi K, et al. Functional expression of Candida albicans drug effl ux pump Cdr1p in Saccharomyces cerevisiae strain defi cient in membrane transporters. Antimicrobiol Agents Chemother 2001; 45: 3366-3374. (Pubitemid 33107848)
38. Gauthier C, Weber S, Alarco AM, et al. Functional similarities and differences between Candida albicans Cdr1p and Cdr2p transporters. Antimicrob Agents Chemother 2003; 47: 1543-1554. (Pubitemid 36548535)
39. Ivnitski-Steele I, Holmes AR, Lamping E, e t al. Identifi cation of Nile red as a fl uorescent substrate of the Candida albicans ATP-binding cassette transporters Cdr1p and Cdr2p and the major facilitator superfamily transporter Mdr1p. Analyt Biochem 2009; 394: 87-91.
40. Gulsham K, Moye-Rowley WS. Multidrug resistance in fungi. Eucaryotic Cell 2007; 6: 1933-1942. (Pubitemid 350221262)
41. Willocks L, Leen CL, Brettle RP, et al. Fluconazole resistance in AIDS patients. J Antimicrob Chemother 1991; 28: 937-939.
42. Pinjon E, Moran GP, Coleman DC, Sullivan DJ. Azole susceptibility and resistance in Candida dubliniensis. Biochem Soc Trans 2005; 33: 1210-1214. (Pubitemid 41659151)
43. Ben-Yaacov RS, Knoller S, Caldwell GA, Becker JM, Koltin Y. C andida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene. Antimicrobiol Agents Chemother 1994; 38: 648-652. (Pubitemid 24113995)
44. Fling ME, Kopf J, Tamarkin A, e t al. Analysis of a C andida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Mol Gen Genet 1991; 227: 318-329.
45. Franz R, Kelly SL, Lamb DC, et al. Multiple molecular mechanisms contribute to a stepwise development of fl uconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother 1998; 42: 3065-3072. (Pubitemid 28553719)
46. Franz R, Ruhnke M, Morschhauser J. Molecular aspects of fl uconazole resistance development in Candida albicans. Mycoses 1999; 42: 453-458. (Pubitemid 29470386)
47. Lopez-Ribot JL, McAtee RK, Lee LN, et al. Distinct patterns of gene expression associated with development of fl uconazole resistance in serial Candida albicans isolates from human immunodefi ciency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 1998; 42: 2932-2937. (Pubitemid 28501228)
48. Perea S, Lopez-Ribot JL, Kirkpatrick WR. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fl uconazole resistance isolated from human immunodefi ciency virus-infected patients. Antimicrob Agents Chemother 2001; 45: 2676-2684. (Pubitemid 32906656)
49. Sanglard D, Kuchler K, Ischer F, et al. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specifi c multidrug transporters. Antimicrob Agents Chemother 1995; 39: 2378-2386.
50. White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodefi ciency virus. Antimicrob Agents Chemother 1997; 41: 1482-1487. (Pubitemid 27289672)
51. Wirsching S, Michel S, Morschhauser J. Targeted gene disruption in Candida albicans wild-type strains: the role of the MDR1 gene in fl uconazole resistance of clinical Candida albicans isolates. Mol Microbiol 2000; 36: 856-865. (Pubitemid 30326531)